Australia Market Report for Assisted Reproduction Technology 2017 - MedCore

Australia Market Report for Assisted Reproduction Technology 2017 - MedCore

  • May 2017 •
  • 260 pages •
  • Report ID: 4895088

Assisted reproduction technologies (ART) help women or couples conceive children. Most couples who use ART are affected by infertility, although ART can also be used to help lesbian couples or single women. A couple is considered to be infertile if they have not conceived after one year of intercourse without birth control.
While there are a number of techniques used to aid fertilization, the products discussed in this chapter are those used for in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). An IVF procedure removes the woman’s eggs and then fertilizes them with sperm in a lab setting. IVF has been very successful in helping couples become pregnant within their first or second cycle. ICSI takes a sperm cell and injects it directly into an egg. ICSI can facilitate fertilization in conjunction with IVF.

General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions

The assisted reproduction market consists of the oocyte retrieval needle, micropipette, embryo transfer catheter, reproductive media and embryo time-lapse incubator sub-segments. The market value of assisted reproduction devices is tied to the number of cycles performed. In this report, the cycle procedure numbers include both IVF and ICSI cycles. In assisted reproductive technology, there is no international, or in many cases, national standard protocols in place. This means that labs vary by technique, equipment, types and units of supplies used etc. Part of the differences between country market values is due to procedure number variations, and part of the difference is due to the variations in common lab processes between countries.

Reimbursement is one of the predominant factors affecting the number of IVF cycles performed annually and the number of patients seeking treatment. In Australia, reimbursement is available through both public and private insurance; however, it rarely covers 100% of the costs. The remaining amount will be covered out-of-pocket by the patient. Many other factors are also limited by governments. The number of cycles attempted before pregnancy varies by country, the number of embryos implanted and the age of the potential parents is also a factor. Also, some companies only reimburse certain types of procedures or reimburse some procedures at better rates. Excluding the cost of capital equipment and doctor’s fees, there is still a large profit margin to be had by ART clinics.

Assisted reproduction tourism is both helping and hurting the Australian market. As a western, developed country, fewer patients leave Australia seeking IVF than in most countries in Asia/Oceania. However, sex selection through ART is illegal and strictly enforced in Australia. Patients that are hard set on gender selection will still seek treatment in neighboring countries such as Thailand, Singapore, Vietnam and the Philippine’s. Sex selection for IVF is also illegal in neighboring countries; however, with lower salaries and less due diligence enforcing regulations, it is common practice that additional payments can be made for sex selection.

Alternatively, Australia also experiences an increase in patients travelling from China for IVF treatments. China’s population is growing with an expanding, wealthier, middle class now able to afford assisted reproduction treatments. The number of doctors and clinics in China are over-booked causing patients to seek treatments abroad.